Patient-Factors Influencing the 2-Year Trajectory of Mental and Physical Health in Prostate Cancer Patients.

SF-12 growth mixture model health related quality of life prostate cancer

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
31 10 2022
Historique:
received: 06 09 2022
revised: 12 10 2022
accepted: 26 10 2022
entrez: 10 11 2022
pubmed: 11 11 2022
medline: 15 11 2022
Statut: epublish

Résumé

This study aimed to examine the physical and mental Quality of Life (QoL) trajectories in prostate cancer (PCa) patients participating in the Pros-IT CNR study. QoL was assessed using the Physical (PCS) and Mental Component Score (MCS) of Short-Form Health Survey upon diagnosis and two years later. Growth mixture models were applied on 1158 patients and 3 trajectories over time were identified for MCS: 75% of patients had constantly high scores, 13% had permanently low scores and 12% starting with low scores had a recovery; the predictors that differentiated the trajectories were age, comorbidities, a family history of PCa, and the bowel, urinary and sexual functional scores at diagnosis. In the physical domain, 2 trajectories were defined: 85% of patients had constantly high scores, while 15% started with low scores and had a further slight decrease. Two years after diagnosis, the psychological and physical status was moderately compromised in more than 10% of PCa patients. For mental health, the trajectory analysis suggested that following the compromised patients at diagnosis until treatment could allow identification of those more vulnerable, for which a level 2 intervention with support from a non-oncology team supervised by a clinical psychologist could be of help.

Identifiants

pubmed: 36354711
pii: curroncol29110651
doi: 10.3390/curroncol29110651
pmc: PMC9689299
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8244-8260

Références

Urology. 2005 Aug;66(2):338-43
pubmed: 16098363
BJU Int. 2014 Dec;114(6b):E74-E81
pubmed: 24588845
J Cancer Surviv. 2016 Apr;10(2):406-15
pubmed: 26428396
Int J Cancer. 2017 Apr 1;140(7):1517-1527
pubmed: 28006843
Int Braz J Urol. 2020 Nov-Dec;46(6):993-1005
pubmed: 32822128
BMJ Open. 2014 Mar 13;4(3):e003901
pubmed: 24625637
BMC Public Health. 2018 Aug 23;18(1):1060
pubmed: 30139347
Int J Behav Dev. 2009;33(6):565-576
pubmed: 23885133
Health Qual Life Outcomes. 2019 Jan 14;17(1):11
pubmed: 30642340
Implement Sci. 2018 Jul 26;13(1):98
pubmed: 30045735
Biopsychosoc Med. 2007 Jan 10;1:2
pubmed: 17371571
Support Care Cancer. 2021 Feb;29(2):645-651
pubmed: 32424643
Soc Sci Med. 2006 Aug;63(4):911-9
pubmed: 16798130
Clin Epidemiol. 2020 Oct 30;12:1205-1222
pubmed: 33154677
BMC Med Res Methodol. 2021 Apr 21;21(1):79
pubmed: 33882863
Eur Urol. 2017 Feb;71(2):274-280
pubmed: 27720532
Cancers (Basel). 2021 Mar 23;13(6):
pubmed: 33806994
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Control Clin Trials. 1989 Dec;10(4):407-15
pubmed: 2691207
COPD. 2005 Mar;2(1):57-62
pubmed: 17136963
Health Qual Life Outcomes. 2018 Jun 13;16(1):122
pubmed: 29898750
Prostate Cancer Prostatic Dis. 2012 Jun;15(2):120-7
pubmed: 22212706
BMJ. 2019 Jan 25;364:l408
pubmed: 30683652
Radiother Oncol. 2013 Aug;108(2):306-13
pubmed: 23849168
BJU Int. 2016 Jun;117(6B):E10-9
pubmed: 25818406
Qual Life Res. 2016 Sep;25(9):2379-93
pubmed: 26908258
Tumori. 2015 Mar-Apr;101(2):223-31
pubmed: 25702659
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Eur Urol. 2015 Oct;68(4):600-8
pubmed: 25242555
Br J Cancer. 2006 Apr 24;94(8):1093-8
pubmed: 16622434
Asia Pac J Oncol Nurs. 2017 Oct-Dec;4(4):313-318
pubmed: 28966959
BJU Int. 2011 Apr;107(8):1223-31
pubmed: 21070583
Support Care Cancer. 2018 Apr;26(4):1297-1304
pubmed: 29127529
Eur Urol. 2015 Apr;67(4):637-45
pubmed: 25454617
Aging Clin Exp Res. 2017 Apr;29(2):165-172
pubmed: 28236267
J Clin Epidemiol. 1998 Nov;51(11):1171-8
pubmed: 9817135
JAMA. 2020 Jan 14;323(2):149-163
pubmed: 31935027
Psychooncology. 2017 Oct;26(10):1576-1585
pubmed: 27943512
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Urol Oncol. 2015 Feb;33(2):69.e19-28
pubmed: 24433753

Auteurs

Alessandro Cicchetti (A)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Marianna Noale (M)

Aging Branch, Neuroscience Institute, National Research Council, 35128 Padua, Italy.

Paola Dordoni (P)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Barbara Noris Chiorda (B)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Letizia De Luca (L)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Lara Bellardita (L)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Rodolfo Montironi (R)

Molecular Medicine and Cell Therapy Foundation c/o, Polytechnic University of the Marche Region, 60121 Ancona, Italy.

Filippo Bertoni (F)

Prostate Group, Italian Association for Radiation Oncology (AIRO), 20124 Milan, Italy.

Pierfrancesco Bassi (P)

Department of Urology, Policlinico Gemelli, Catholic University of Rome, 00168 Rome, Italy.

Riccardo Schiavina (R)

Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

Mauro Gacci (M)

Department of Urologic Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, 50134 Florence, Italy.

Sergio Serni (S)

Department of Urologic Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, 50134 Florence, Italy.

Francesco Sessa (F)

Department of Urologic Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, 50134 Florence, Italy.

Marco Maruzzo (M)

Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

Stefania Maggi (S)

Aging Branch, Neuroscience Institute, National Research Council, 35128 Padua, Italy.

Riccardo Valdagni (R)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122 Milan, Italy.
Unit of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH